Pegademase Bovine

Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Caution and personalized dose adjustment in patients with the following genotypes
  • Other genes that may be involved
  • Drug Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names

North America

USA: Adagen.

Drug combinations


Pegademase Bovine: Adenosine deaminase is obtained from calf intestine. (1) Deaminase, adenosine, cattle, reaction product with succinic anhydride, esters with polyethylene glycol mono-methyl ether; (2) Polyethylene glycol-modified adenosine deaminase. CAS-130167-68-9 (1990).

Pharmacologic Category

Enzymes. (ATC-Code: L03AX04).

Mechanism of action

A (modified) enzyme replacement for adenosine deaminase deficiency.

Therapeutic use

Enzyme replacement therapy for adenosine deaminase deficiency in severe combined immunodeficiency disease.

Pregnancy and lactiation implications

Animal studies not conducted. There are no adequate, well-controlled studies in pregnant women. Benefits vs risks should be considered carefully. Excretion in breast milk unknown (use caution).

Unlabeled use


Not to be used as preparatory or support therapy for bone marrow transplantation. Severe thrombocytopenia.

Warnings and precautions

Development of antibodies reported in patients resulting in more rapid clearance of pegademase bovine. Failure to maintain adequate levels of plasma adenosine deaminase will increase risk for infection. Use with caution in thrombocytopenia (should not be used in severe thrombocytopenia). Not substitute for bone marrow transplant.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart